Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations
Understanding how genetic factors contribute to disease risk improves our understanding of pathogenesis, supports drug development, and aids risk prediction (1). Appropriate quantification and interpretation of this contribution is essential for measuring the impact of genetic variation and in motivating and informing future studies.
R.J.A. is an Action for Pulmonary Fibrosis Research Fellow. L.V.W. holds a GlaxoSmithKline/British Lung Foundation Chair in Respiratory Research (C17-1). R.G.J. is supported by a National Institute for Health Research (NIHR) Research Professorship (NIHR reference RP-2017-08-ST2-014). I.N. is supported by NHLBI grant R01HL130796. C.F. is supported by the Spanish Ministry of Science and Innovation (grant RTC-2017-6471-1; Agencia Estatal de Investigaci ´on/Fondo Europeo de Desarrollo Regional, UE), cofinanced by the European Regional Development Funds “A way of making Europe” from the European Union, and by the agreement OA17/008 with Instituto Tecnol ´ogico y de Energ´ıas Renovables to strengthen scientific and technological education, training, research, development, and innovation in Genomics, Personalized Medicine, and Biotechnology. P.L.M. is an Action for Pulmonary Fibrosis Research Fellow. T.M.M. is supported by an NIHR Clinician Scientist Fellowship (NIHR Ref: CS-2013-13-017) and a British Lung Foundation Chair in Respiratory Research (C17-3). J.M.O. is supported by NHLBI grant K23HL138190.
CitationAmerican Journal of Respiratory and Critical Care Medicine, 203 (6), pp. 775-778https://doi.org/10.1164/rccm.202008-3211LE
Author affiliationDepartment of Health Sciences, University of Leicester
- VoR (Version of Record)